SCHEMBL3401432

SCHEMBL3401432

CCCC(N)Cc1ccccc1

nearest known ligand 0.96

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.67
ANPEP P15144 1/20 0.57
SIGMAR1 Q99720 4/20 0.56
SLC6A2 P23975 2/20 0.56
TAAR1 Q96RJ0 2/20 0.56
MAOA P21397 1/20 0.56
SLC6A4 P31645 1/20 0.56
SLC6A3 Q01959 1/20 0.56
CYP2A6 P11509 1/20 0.56
ADORA2A P29274 1/20 0.56
ADORA1 P30542 1/20 0.56
CSNK1E P49674 1/20 0.54
CYP2D6 P10635 1/20 0.52
SCN4A P35499 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL172452 1.00 EPHX1 (0.67) EPHX1ANPEPSIGMAR1SLC6A2TAAR1
SCHEMBL14471186 1.00 EPHX1 (0.67) EPHX1ANPEPSIGMAR1SLC6A2TAAR1
Hydrochloric Acid SCHEMBL6659825 0.98 EPHX1 (0.64) EPHX1ANPEPSIGMAR1SLC6A2TAAR1
Bromide SCHEMBL6947335 0.98 EPHX1 (0.64) EPHX1ANPEPSIGMAR1SLC6A2TAAR1
SCHEMBL2736211 0.96 EPHX1 (0.61) EPHX1ANPEPSIGMAR1SLC6A2TAAR1
Bicarbonate SCHEMBL3217828 0.89 EPHX1 (0.53) EPHX1ANPEPSIGMAR1SLC6A2TAAR1
SCHEMBL9468396 0.88 EPHX1 (0.52) EPHX1ANPEPSIGMAR1SLC6A2TAAR1
SCHEMBL21469786 0.88 EPHX1 (0.61) EPHX1ANPEPSIGMAR1SLC6A2TAAR1
SCHEMBL3847568 0.88 EPHX1 (0.61) EPHX1ANPEPSIGMAR1SLC6A2TAAR1
Hydrochloric Acid SCHEMBL9468395 0.87 EPHX1 (0.50) EPHX1ANPEPSIGMAR1SLC6A2TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1882000-B1 CATALYST COMPOSITION FOR OLEFIN POLYMERIZATION NOVOLEN TECH HOLDINGS CV (NL) 2010-03-31 EP claimed
EP-0387178-B9 Process for the preparation of clavulinic acid and pharmaceutically acceptable salts from fermentation broths of Streptomyces sp. SMITHKLINE BEECHAM PLC (GB) 2002-09-25 EP claimed
EP-0387178-B2 Process for the preparation of clavulinic acid and pharmaceutically acceptable salts from fermentation broths of Streptomyces sp. SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP claimed
EP-0387178-B1 Process for the preparation of clavulinic acid and pharmaceutically acceptable salts from fermentation broths of Streptomyces sp. SMITHKLINE BEECHAM PLC (GB) 1997-01-02 EP claimed
EP-4736988-A1 ACIDIC GAS-ABSORBING LIQUID AND ACIDIC GAS REDUCTION METHOD AGC INC. (JP) 2026-05-06 EP disclosed
US-20260115649-A1 ACIDIC GAS-ABSORBING LIQUID AND ACIDIC GAS REDUCTION METHOD AGC Inc. (JP) 2026-04-30 US disclosed
WO-2025004799-A1 ACIDIC GAS-ABSORBING LIQUID AND ACIDIC GAS REDUCTION METHOD AGC株式会社 2025-01-02 WO disclosed
EP-3872064-B1 FLUORINATED IMIDE SALT COMPOUND AND SURFACTANT MITSUBISHI MAT ELECTRONIC CHEMICALS CO LTD (JP) 2023-09-20 EP disclosed
CN-115745842-A Method for synthesizing aromatic carbamate through photocatalysis 华南理工大学 2023-03-07 CN disclosed
CN-112996772-B Fluorine-containing imide salt compound and surfactant 三菱材料电子化成株式会社 2022-10-28 CN disclosed
US-11414381-B2 Fluorinated imide salt compound and surfactant MITSUBISHI MATERIALS ELECTRONIC CHEMICALS CO., LTD. (JP) 2022-08-16 US disclosed
CN-107709424-B Systems and methods for producing aerogel materials 气凝胶科技有限责任公司 2022-08-02 CN disclosed
US-6057371-A TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS, DRUG ABUSE, ANGINA, MIGRAINE, HYPERTENSION AND DEPRESSION VIRGINIA COMMONWEALTH UNIVERSITY (US) 2000-05-02 US disclosed
US-5972953-A MORPHINAN DERIVATIVE; USEFAL AS PREVENTIVE AND THERAPUETIC AGENTS OF ISCHEMIC BRAIN DISORDERS, BRAIN NERVE CELL DISORDERS AND DEMENTIA TORAY INDUSTRIES, LTD. (JP) 1999-10-26 US disclosed
US-5952152-A POLYMERIZABLE MIXTURE COMPRISING AT LEAST ONE ETHYLENICALLY UNSATURATED COMPOUND AND AN ANIONIC BORON COMPOUND ACTIVATOR CIBA SPECIALTY CHEMICALS CORPORATION (US) 1999-09-14 US disclosed
EP-0896587-A1 POLYMERISABLE COMPOSITION Ciba SC Holding AG (CH) 1999-02-17 EP disclosed
EP-0661283-B1 BRAIN CELL PROTECTIVE TORAY INDUSTRIES (JP) 1998-10-21 EP disclosed
WO-1997042227-A1 POLYMERISABLE COMPOSITION CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1997-11-13 WO disclosed
EP-0661283-A1 BRAIN CELL PROTECTIVE TORAY INDUSTRIES, INC. (JP) 1995-07-05 EP disclosed
US-4980493-A Process for preparing benzonitriles ICI AUSTRALIA LIMITED (AU) 1990-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11414381-B2 Fluorinated imide salt compound and surfactant NHERF1, AFF1, SCN1A EPHX1 4417/4885ANPEP 1289/4885SIGMAR1 147/4885
US-20260115649-A1 ACIDIC GAS-ABSORBING LIQUID AND ACIDIC GAS REDUCTION METHOD CA7, CA9, CA12 EPHX1 2863/4885ANPEP 1127/4885SIGMAR1 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.